{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:12:37Z","timestamp":1789924357916,"version":"4.0.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01329-w","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T17:34:40Z","timestamp":1772127280000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical and molecular characteristics of Class II and III BRAF mutations in colorectal cancer"],"prefix":"10.1038","volume":"10","author":[{"given":"Ibrahim Halil","family":"Sahin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Xiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Baca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moh\u2019d","family":"Khushman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Grothey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafia","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Akce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Gorantla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anup","family":"Kasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony F.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Oberley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Sledge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Paul","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwaar","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammedtaki","family":"Tejani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"1329_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"1329_CR2","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.3967","volume":"21","author":"J Guinney","year":"2015","unstructured":"Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350\u20131356 (2015).","journal-title":"Nat. Med."},{"key":"1329_CR3","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1080\/17474124.2019.1663174","volume":"13","author":"I Guler","year":"2019","unstructured":"Guler, I., Askan, G., Klostergaard, J. & Sahin, I. H. Precision medicine for metastatic colorectal cancer: an evolving era. Expert Rev. Gastroenterol. Hepatol. 13, 919\u2013931 (2019).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"1329_CR4","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1200\/OP.21.00160","volume":"17","author":"IH Sahin","year":"2021","unstructured":"Sahin, I. H. & Klostergaard, J. BRAF mutations as actionable targets: a paradigm shift in the management of colorectal cancer and novel avenues. JCO Oncol. Pract. 17, 723\u2013730 (2021).","journal-title":"JCO Oncol. Pract."},{"key":"1329_CR5","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1200\/OP.21.00904","volume":"18","author":"C Karan","year":"2022","unstructured":"Karan, C. et al. Human Epidermal growth factor receptor 2\u2013targeting approaches for colorectal cancer: Clinical implications of novel treatments and future therapeutic avenues. JCO Oncol. Pract. 18, 545\u2013554 (2022).","journal-title":"JCO Oncol. Pract."},{"key":"1329_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2212419","volume":"388","author":"R Yaeger","year":"2023","unstructured":"Yaeger, R. et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N. Engl. J. Med. 388, 44\u201354 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1329_CR7","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","volume":"389","author":"MG Fakih","year":"2023","unstructured":"Fakih, M. G. et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C. N. Engl. J. Med. 389, 2125\u20132139 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1329_CR8","doi-asserted-by":"crossref","unstructured":"Kopetz, S. et al. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial. Nature medicine. 2025:1-8.","DOI":"10.1038\/s41591-024-03443-3"},{"key":"1329_CR9","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","volume":"16","author":"C Cremolini","year":"2015","unstructured":"Cremolini, C. et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 16, 1306\u20131315 (2015).","journal-title":"Lancet Oncol."},{"key":"1329_CR10","doi-asserted-by":"publisher","first-page":"4618","DOI":"10.1158\/1078-0432.CCR-21-2138","volume":"28","author":"PI Poulikakos","year":"2022","unstructured":"Poulikakos, P. I., Sullivan, R. J. & Yaeger, R. Molecular pathways and mechanisms of BRAF in cancer therapy. Clin. Cancer Res. 28, 4618\u20134628 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1329_CR11","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","volume":"381","author":"S Kopetz","year":"2019","unstructured":"Kopetz, S. et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E\u2013mutated colorectal cancer. N. Engl. J. Med. 381, 1632\u20131643 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1329_CR12","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa2501912","volume":"392","author":"E Elez","year":"2025","unstructured":"Elez, E. et al. Encorafenib, cetuximab, and mFOLFOX6 in BRAF-mutated colorectal cancer. N. Engl. J. Med. 392, 2425\u20132437 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1329_CR13","doi-asserted-by":"publisher","first-page":"7089","DOI":"10.1158\/1078-0432.CCR-19-2004","volume":"25","author":"R Yaeger","year":"2019","unstructured":"Yaeger, R. et al. Response to anti-EGFR therapy in patients with BRAF non-V600\u2013mutant metastatic colorectal cancer. Clin. Cancer Res. 25, 7089\u20137097 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1329_CR14","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nature23291","volume":"548","author":"Z Yao","year":"2017","unstructured":"Yao, Z. et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature 548, 234\u2013238 (2017).","journal-title":"Nature"},{"key":"1329_CR15","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1200\/JCO.2016.71.4394","volume":"35","author":"JC Jones","year":"2017","unstructured":"Jones, J. C. et al. Non-V600BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer. J. Clin. Oncol. 35, 2624 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1329_CR16","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1158\/1055-9965.EPI-18-1383","volume":"28","author":"M Yang","year":"2019","unstructured":"Yang, M. et al. Repurposing EGFR inhibitor utility in colorectal cancer in mutant APC and TP53 subpopulations. Cancer Epidemiol. Biomark. Prev. 28, 1141\u20131152 (2019).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"1329_CR17","doi-asserted-by":"publisher","first-page":"3954","DOI":"10.1158\/1078-0432.CCR-19-0311","volume":"25","author":"M Schirripa","year":"2019","unstructured":"Schirripa, M. et al. Class 1, 2, and 3 BRAF-mutated metastatic colorectal cancer: a detailed clinical, pathologic, and molecular characterization. Clin. Cancer Res. 25, 3954\u20133961 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1329_CR18","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1200\/JCO.2016.71.4394","volume":"35","author":"JC Jones","year":"2017","unstructured":"Jones, J. C. et al. Non-V600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer. J. Clin. Oncol. 35, 2624\u20132630 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1329_CR19","first-page":"164","volume":"13","author":"V Morris","year":"2014","unstructured":"Morris, V. et al. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin. Colorectal Cancer 13, 164\u2013171 (2014).","journal-title":"Clin. Colorectal Cancer"},{"key":"1329_CR20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/oncolo\/oyab055","volume":"27","author":"E Tan","year":"2022","unstructured":"Tan, E. et al. BRAF mutations are associated with poor survival outcomes in advanced-stage mismatch repair-deficient\/microsatellite high colorectal cancer. Oncologist 27, 191\u2013197 (2022).","journal-title":"Oncologist"},{"key":"1329_CR21","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1158\/2159-8290.CD-24-0024","volume":"14","author":"R Yaeger","year":"2024","unstructured":"Yaeger, R. et al. A next-generation BRAF inhibitor overcomes resistance to BRAF inhibition in patients with BRAF-mutant cancers using pharmacokinetics-informed dose escalation. Cancer Discov. 14, 1599\u20131611 (2024).","journal-title":"Cancer Discov."},{"key":"1329_CR22","doi-asserted-by":"crossref","unstructured":"Franovic, A. et al. The Next-generation Pan-RAF Inhibitor, KIN-2787, is Active in Class II and Class III BRAF Mutant Models. (Wolters Kluwer Health, 2021).","DOI":"10.1200\/JCO.2021.39.15_suppl.3116"},{"key":"1329_CR23","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.1158\/0008-5472.CAN-08-4765","volume":"69","author":"S Wee","year":"2009","unstructured":"Wee, S. et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res. 69, 4286\u20134293 (2009).","journal-title":"Cancer Res."},{"key":"1329_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade\u2013based immunotherapy. Science 362, eaar3593 (2018).","journal-title":"Science"},{"key":"1329_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-020-00787-6","volume":"12","author":"R Bao","year":"2020","unstructured":"Bao, R., Stapor, D. & Luke, J. J. Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types. Genome Med. 12, 1\u201319 (2020).","journal-title":"Genome Med."},{"key":"1329_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-018-0051-4","volume":"2","author":"M-C Wagle","year":"2018","unstructured":"Wagle, M.-C. et al. A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types. NPJ Precis. Oncol. 2, 7 (2018).","journal-title":"NPJ Precis. Oncol."},{"key":"1329_CR27","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/cam4.1372","volume":"7","author":"A Vanderwalde","year":"2018","unstructured":"Vanderwalde, A., Spetzler, D., Xiao, N., Gatalica, Z. & Marshall, J. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Med. 7, 746\u2013756 (2018).","journal-title":"Cancer Med."},{"key":"1329_CR28","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s41416-024-02826-0","volume":"131","author":"S Chowdhury","year":"2024","unstructured":"Chowdhury, S. et al. Consensus molecular subtyping of metastatic colorectal cancer expands biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumors. Br. J. Cancer 131, 1328\u20131339 (2024).","journal-title":"Br. J. Cancer"},{"key":"1329_CR29","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417\u2013419 (2017).","journal-title":"Nat. Methods"},{"key":"1329_CR30","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1158\/1078-0432.CCR-20-3286","volume":"27","author":"JP Abraham","year":"2021","unstructured":"Abraham, J. P. et al. Clinical validation of a machine-learning\u2013derived signature predictive of outcomes from first-line oxaliplatin-based chemotherapy in advanced colorectal cancer. Clin. Cancer Res. 27, 1174\u20131183 (2021).","journal-title":"Clin. Cancer Res."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01329-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01329-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01329-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T12:19:49Z","timestamp":1775650789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01329-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1329"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01329-w","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.H.S. has declared Advisory Board fees from Seattle Genetics, Guardant, Amgen, Pfizer and GSK, and Lumanity; research funding from BAYER, Roche, and GSK. M.K. has disclosed consulting or advisory roles at Cardinal Health, Muerus, and TriSalus Life Sciences; stock and other ownership interests from Cardiff Oncology; Speakers' Bureau at Caris Life Sciences; and research funding from Abbvie (Inst), FOGPharma (Inst), IgM Biosciences (Inst), and Torl Biotherapeutics (Inst). A.G. has declared honoraria: Total Health Conferencing, Cardinal Health; consulting or advisory role: Bristol Myers Squibb (Inst), Lilly (Inst), Amgen (Inst), Daiichi Sankyo (Inst), OBI Pharma, Caris Life Sciences (Inst), Guardant Health (Inst), Natera (Inst), Replimune (Inst); research funding: Eisai (Inst), Lilly (Inst), Daiichi Sankyo (Inst), Replimune (Inst), Natera (Inst), Caris Life Sciences (Inst), Guardant Health (Inst); travel, accommodations, expenses: Cardinal Health, Total Health Conferencing. B.A.W. has declared employment: Apple (I); stock and other ownership interests: Apple (I); honoraria: Primum, Caris Life Sciences; consulting or advisory role: Merus NV, DoMore Diagnostics, Foundation Medicine, Agenus, Regeneron, CytoDyn; Speakers' Bureau: Sirtex Medical, Seagen, Merus NV, Daiichi Sankyo\/AstraZeneca, Natera, Jazz Pharmaceuticals, Pfizer; research funding: Ipsen (Inst), Immune System Key (Inst), Merck (Inst), BioXCel therapeutics (Inst); expert testimony: AstraZeneca; travel, accommodations, expenses: Merus NV. M.A. has disclosed consulting or advisory roles at AstraZeneca, Curio Science, Eisai, Exelixis, Genentech, GlaxoSmithKline, Incyte, Ipsen, Isofol Medical, QED Therapeutics, Taiho Pharmaceutical; and research funding from AstraZeneca (Inst), Bayer (Inst), Bellicum Pharmaceuticals (Inst), Boehringer Ingelheim (Inst), Bristol-Myers Squibb-Ono Pharmaceutical (Inst), Eisai (Inst), IMPAC Medical Systems (Inst), Merck Sharp & Dohme (Inst), Pfizer (Inst), Polaris (Inst), RedHill Biopharma (Inst), Syros Pharmaceuticals (Inst), Tesaro (Inst), and Xencor (Inst). A.K. has received grants from Astellas, Panavance, Ability, Novita, Cardiff, Lisata Therapeutics, and Boundless Bio outside the submitted work. No other disclosures were reported. E.L. has disclosed equipment for laboratory-based research 2018-present, Novocure, Ltd; honorarium for panel discussion organized by Antidote Education for a CME module on diagnostics and treatment of HER2+ gastric and colorectal cancers, funded by Daiichi-Sankyo, 2021 (honorarium donated to lab); compensation for scientific review of proposed printed content; Elsevier Publishing and Johns Hopkins Press; consultant, Nomocan Pharmaceuticals (no financial compensation); Institutional Principal Investigator for clinical trials sponsored by Celgene, Novocure, Intima Bioscience, Inc., the National Cancer Institute, and the University of Minnesota membership in the Caris Life Sciences Precision Oncology Alliance (no financial compensation). A.S. has received research grants (to institution) from Merck, AstraZeneca, Bristol Myers Squibb, Exelixis, Clovis, Biontech, Astellas, Dragonfly Therapeutics, Innovent biologics, KAHR medical, Amgen, Celgene, Actuate Therapeutics, Incyte corporation, Seagen, Daiichi Sankyo, and Advisory Board fees from Bristol Myers Squibb, AstraZeneca, Exelixis, Pfizer, and Daiichi Sankyo. J.X., Y.B., E.P., M.O., and G.S. are employees of Caris Life Sciences. The authors declare no other financial or non-financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"146"}}